We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

Moderna stock is undervalued with a $97 price target, strong COVID-19 revenue, promising pipeline, and long-term growth. Read ...

We recently compiled a list of the 10 Oversold Healthcare Stocks To Invest In. In this article, we are going to take a look ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) on November 25 and set a price target of $50.00. The ...

The pharmaceutical industry operates under a complex regulatory landscape, balancing government oversight with self-imposed ...

JPMorgan lowered the firm’s price target on Moderna (MRNA) to $45 from $59 and keeps an Underweight rating on the shares. The firm updated ...

Moderna’s top executives have sought to reassure investors they will be able to carry out the comeback plans announced in ...

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $42.05 which represents a decrease of $-1.61 or -3.69% from the prior close of $43.66. The stock opened at $43.13 and touched a ...

CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other oversold healthcare stocks. The Promising Outlook for Healthcare Investments in 2024 ...

CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: 7 th Annual Evercore ISI HealthCONx ...